

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

### Testing strategies for Lynch syndrome in people with endometrial cancer

#### Stakeholder list

<b>Manufacturer / sponsor</b> The University of Manchester
<b>Manufacturers of related technologies (not included in the scope)</b> Biocartis NV Promega UK Ltd
<b>Professional groups</b> Association of Surgical Oncology British Association of Gynaecological Pathologists British Gynaecological Cancer Society British Society of Gastroenterology Institute of Biomedical Science Royal College of Physicians Royal College of Radiologists UK Cancer Genetics Group UK Clinical Genetics Society
<b>Patient/carer groups</b> The Eve Appeal Ovarian Cancer Action
<b>Research groups</b> Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Review Group University of Exeter Medical School, Health Economics Group
<b>A provider of NHS services in England</b> Oxford University Hospitals NHS Foundation Trust Portsmouth Hospitals NHS Trust
<b>External Assessment Group</b> Warwick Evidence
<b>Others</b> Department of Health and Social Care Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency NHS England Welsh Government

**Definitions:**Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).